NCT03947814View on ClinicalTrials.gov

A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

PHASE1TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

September 9, 2020

Study Completion Date

September 9, 2020

Conditions
Kidney Failure, Chronic
Interventions
DRUG

Pimodivir

Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.

Trial Locations (2)

24105

CRS Clinical Research Services Kiel GmbH, Kiel

81241

APEX GmbH, München

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY